Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUPANET adjuvant capecitabine + temozolomide for resected aggressive pancreatic neuroendocrine tumors
2025-523593-16-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine and temozolomide in islet cell tumor (3 arms), sponsored by Gustave Roussy. Primary endpoints: Disease-free survival (DFS) - ADJUPANET randomized arm and Disease-free survival (DFS) - ADJUPANET-OBS observational cohort. Planned start Jun 2026; status: authorised.
02
Drugs
capecitabinetemozolomide
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2025-523593-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523593-16-00.